HLA-A and esophageal squamous cell carcinoma: Accordingly, in the current randomized, placebo-controlled phase 3 study, we aimed to evaluate the efficacy, immune response, and safety of S-588410 as an adjuvant monotherapy for HLA-A*24:02-positive patients with completely resected ESCC.